within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE04_Nelfinavir;

model Nelfinavir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 7.77777777777778e-06,
    adminDuration = 600,
    adminMass = 750 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008,
    Tlag = 20.400000000000002,
    Vdp = 0.0022,
    k12 = 2.858333333333333e-05,
    k21 = 2.858333333333333e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Nelfinavir</td></tr><tr><td>ATC code:</td><td>J05AE04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>750</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.4</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Nelfinavir is an orally administered HIV-1 protease inhibitor that was previously used in combination antiretroviral therapy for the treatment of HIV infection. It is less commonly used today due to the availability of newer agents with improved safety and efficacy profiles.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration in fasting state.</p><h4>References</h4><ol><li><p>Pfister, M, et al., &amp; Sheiner, LB (2003). Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. <i>Antimicrobial agents and chemotherapy</i> 47(1) 130–137. DOI:<a href=\"https://doi.org/10.1128/AAC.47.1.130-137.2003\">10.1128/AAC.47.1.130-137.2003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12499180/\">https://pubmed.ncbi.nlm.nih.gov/12499180</a></p></li><li><p>Jackson, KA, et al., &amp; Dudley, MN (2000). A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. <i>Antimicrobial agents and chemotherapy</i> 44(7) 1832–1837. DOI:<a href=\"https://doi.org/10.1128/AAC.44.7.1832-1837.2000\">10.1128/AAC.44.7.1832-1837.2000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10858338/\">https://pubmed.ncbi.nlm.nih.gov/10858338</a></p></li><li><p>Hirt, D, et al., &amp; Treluyer, JM (2007). Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. <i>British journal of clinical pharmacology</i> 64(5) 634–644. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2007.02885.x\">10.1111/j.1365-2125.2007.02885.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17892516/\">https://pubmed.ncbi.nlm.nih.gov/17892516</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AE04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Nelfinavir;
